Wedbush Keeps a Buy Rating on Intercept Pharma

By Austin Angelo

Wedbush analyst Liana Moussatos reiterated a Buy rating on Intercept Pharma (NASDAQ: ICPT) today. The company’s shares opened today at $128.

According to, Moussatos is a 5-star analyst with an average return of 12.0% and a 46.3% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Catabasis Pharmaceuticals, and miRagen Therapeutics Inc.

Currently, the analyst consensus on Intercept Pharma is Moderate Buy and the average price target is $163.40, representing a 27.7% upside.

In a report issued on July 17, Oppenheimer also maintained a Buy rating on the stock with a $200 price target.

The company has a one year high of $177.93 and a one year low of $96.63. Currently, Intercept Pharma has an average volume of 360K.

Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2017, Lisa Bright, the Chief Commercial & Corporate Affairs Officer of ICPT sold 426 shares for a total of $48,564.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intercept Pharmaceuticals is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.